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OBJECTIVE—Type 2 diabetes is characterized by insulin re-
sistance with a relative deﬁciency in insulin secretion. This study
explored the potential communication between insulin-resistant
human skeletal muscle and primary (human and rat) b-cells.
RESEARCH DESIGN AND METHODS—Human skeletal mus-
cle cells were cultured for up to 24 h with tumor necrosis factor
(TNF)-a to induce insulin resistance, and mRNA expression for
cytokines was analyzed and compared with controls (without
TNF-a). Conditioned media were collected and candidate cyto-
kines were measured by antibody array. Human and rat primary
b-cells were used to explore the impact of exposure to condi-
tioned media for 24 h on apoptosis, proliferation, short-term in-
sulin secretion, and key signaling protein phosphorylation and
expression.
RESULTS—Human myotubes express and release a different
panel of myokines depending on their insulin sensitivity, with
each panel exerting differential effects on b-cells. Conditioned
medium from control myotubes increased proliferation and
glucose-stimulated insulin secretion (GSIS) from primary b-cells,
whereas conditioned medium from TNF-a–treated insulin-resistant
myotubes (TMs) exerted detrimental effects that were either in-
dependent (increased apoptosis and decreased proliferation) or
dependent on the presence of TNF-a in TM (blunted GSIS).
Knockdown of b-cell mitogen-activated protein 4 kinase 4 pre-
vented these effects. Glucagon-like peptide 1 protected b-cells
against decreased proliferation and apoptosis evoked by
TMs, while interleukin-1 receptor antagonist only prevented
the latter.
CONCLUSIONS—Taken together, these data suggest a possible
new route of communication between skeletal muscle and b-cells
that is modulated by insulin resistance and could contribute to
normal b-cell functional mass in healthy subjects, as well as the
decrease seen in type 2 diabetes. Diabetes 60:1111–1121, 2011
R
egulation of b-cell function and mass represent
a critical issue for understanding diabetes, a dis-
ease characterized in its two major forms by
a relative or absolute deﬁciency in the number
of pancreatic b-cells and their function. Type 1 (insulin-
dependent) diabetes thus results from autoimmune de-
struction of pancreatic b-cells (1), and it is now recognized
that there is decreased b-cell mass and function in type 2
diabetes (2) but the precise underlying mechanism re-
mains to be determined. Insulin resistance is obviously
a key player in type 2 diabetes, but it also plays a larger
role in the disease process of type 1 diabetes than is
commonly recognized (3).
Far from being an inert tissue in terms of interorgan
communication, it is now recognized that skeletal muscle
can secrete so-called myokines, which can impact both
favorably and unfavorably on the function of distant
organs/tissues. Interleukin (IL)-6 is the prototype myokine
and was identiﬁed as the ﬁrst long-searched-for muscle
contraction–induced factor (4). It has been suggested that
IL-6 impacts on b-cell function, but more detailed studies
are needed to clarify the direct impact of this cytokine on
pancreatic b-cells in health and disease, especially be-
cause the a-cell has been identiﬁed as a major IL-6 target
in islets (5). Adiponectin, ﬁrst identiﬁed as a secretory
product of adipocytes, has also been shown to be secreted
by skeletal muscles (6) and can impact positively on pan-
creatic b-cell function and survival (7).
More generally, studies performed in vitro have con-
ﬁrmed that various cytokines and chemokines can impact
positively or negatively on the function, survival, and pro-
liferation of b-cells (8), including IL-1b (9), IL-6 (5,10),
adiponectin (7), and tumor necrosis factor-a (TNF-a), (11)
as well as chemokine (C-C motif) ligand 5 (CCL5), mono-
cyte chemoattractant protein-1 (MCP-1), IL-8, and CXC
chemokine ligand (CXCL10) (12,13). This raises the pos-
sibility of beneﬁcial or detrimental effects of cytokines on
b-cells depending on concentration and biological context.
Skeletal muscle plays a major role in whole-body sub-
strate homeostasis in the postprandial state, and impaired
action on this tissue contributes to the pathological con-
dition of insulin resistance (14). The recent identiﬁcation
of skeletal muscle as an endocrine organ that produces
and releases myokines expands our knowledge of how the
nervous, endocrine, and immune systems contribute to the
maintenance of homeostasis, also when challenged by
changing physiological demands (4). Given that skeletal
muscle is the prevalent organ in the human body in terms
of its mass, we decided to explore if skeletal muscle with
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ORIGINAL ARTICLEdistinct insulin sensitivity can differentially impact on b-cell
function.
During the last years, multiple studies have been per-
formed to understand the mechanism of insulin resistance
(15). We showed previously that TNF-a can induce insulin
resistance in human skeletal muscle by altering the insulin
signaling pathway (16), providing a unique system for mo-
lecular dissection in vitro (17). The physiological source of
increased circulating levels of TNF-a in type 2 diabetes
remains unclear, but it does not appear to be the muscle
itself (18). TNF-a is, however, believed to be a major cy-
tokine involved in the “conversation” between adipose
tissue and muscle with increased levels in obesity and type
2 diabetes possibly contributing to insulin resistance in
skeletal muscle (19).
With this background in mind, we have used this vali-
dated in vitro model of skeletal muscle insulin resistance
to explore putative conversation between skeletal muscle
and b-cells. A different panel of myokines is secreted by
normally sensitive or insulin-resistant myotubes that im-
pact in a beneﬁcial or detrimental way, respectively, on
b-cell function, proliferation, and survival.
RESEARCH DESIGN AND METHODS
Antibodies and reagents. The antibodies and reagents were as follows:
human TNF (hTNF)-a (R&D Systems Europe Ltd., Abingdon, U.K.); anti-
phospho–Akt-(Ser473), anti-phospho–ERK-1/2-(Thr202/Tyr204) (New England
Biolabs, Beverly, MA); anti-phospho–(Ser/Thr)-AS160, anti-AS160, anti-Akt, anti-
ERK, anti–insulin receptor substrate (IRS)-2 (Cell Signaling Technology, Beverly,
MA); antiactin (Sigma, Buchs, Switzerland); anti–IRS-1 (gift from Dr. M.F.
White; Children’s Hospital, Harvard University, Boston, MA); Ethanercept
(Wyeth Pharmaceuticals SA, Zoug, Switzerland); 5-bromo-2-deoxyuridine
(BrdU) and transferase-mediated dUTP nick-end labeling (TUNEL) kits (Roche,
Mannheim, Germany); IL-1RA (Kineret), Amgen (Breda, the Netherlands); and
glucagon-like peptide 1 (GLP-1) (Bachem, Bubendorf, Switzerland).
Human skeletal muscle cells. Rectus abdominus muscle was obtained with
the informed consent of donors during scheduled abdominal surgery (Geneva
Hospital and Danish Muscle Center approved the study protocols NAC 06–093
and jr. nr. H-A-2007–0016). This particular slow-twitch ﬁber type of skeletal
muscle was chosen for ease of surgical access as well as insulin-sensitive
glucose uptake using in vitro–derived myotubes. The satellite cells were iso-
lated from the muscle biopsies by trypsin digestion and grown in Ham’sF 1 0
medium with 20% FCS and antibiotics. Conﬂuent myoblasts were allowed to
fuse and differentiate into myotubes in Dulbecco’s modiﬁed Eagle’s medium,
2% FCS, and antibiotics. Human myotubes were used 7 days after induction of
differentiation (when most cells are multinucleated) and expressed speciﬁc
human skeletal muscle markers (17).
Oligo GEArray experiments. Total RNA was extracted with the QIAshredder
and RNeasy Mini Kit (QIAGEN, Basel, Switzerland). The UTP-biotinylated
cRNA probe was synthesized with the TrueLabeling-AMP 2.0 Kit (SuperArray,
Frederick, MD) and puriﬁed with the ArrayGrade cRNA Cleanup Kit (Super-
Array). The membranes (focused on human inﬂammatory cytokines and re-
ceptors [OHS-011 from SABiosciences, Frederick, MD]) were hybridized
following the manufacturer’s instructions.
Human chemokine and cytokine antibody arrays. Human chemokine +
human cytokine V arrays (Ray Biotech, Norcross, GA) were used following the
manufacturer’s instructions, and images were quantiﬁed using Multi Gauge
software with intensity normalized to internal controls.
Rat primary b-cell puriﬁcation. Animals were treated according to protocols
approvedbytheState Commissioner onAnimalCare. IsletsofLangerhanswere
isolated by collagenase digestion of pancreas from male Wistar rats (150–200 g)
followed by Ficoll puriﬁcation (20). b-Cells sorted by ﬂuorescence-activated
cell sorter were plated on 804G extracellular matrix (20,21).
Human primary b-cell puriﬁcation. Human islets were provided by the Islet
Cell Resource Centers of Milan (Italy), Geneva (Switzerland), and Lille (France).
Human b-cells were sorted by ﬂuorescence-activated cell sorter to .90% purity
following labeling with Newport Green (21).
Insulin secretion assay and insulin content. Cells were incubated for 1 h at
37°C with Krebs-Ringer bicarbonate buffer with Hepes (KRBH) containing 2.8
mmol/L glucose (basal secretion), followed by 1 h at 37°C with KRBH con-
taining 16.7 mmol/L glucose (stimulated secretion) as previously described
(22). Insulin in incubation buffers and cell extracts was measured by radio-
immunoassay and secretion expressed as percentage total insulin content.
Detection of apoptosis and proliferation. Cell death was measured by
TUNEL assay. Proliferation was assessed by BrdU incorporation (22).
RNA interference mediated silencing of MAP4K4. Knockdown of MAP4K4
in rat primary b-cells was achieved by transfection with small interfering RNA
as previously described (11). All other standard methods were as described
previously (22).
Presentation of data and statistics. Data are mean 6 SEM for 3–5 in-
dependent experiments (2 replicates for each independent experiment for
insulin secretion, BrdU incorporation, and TUNEL assay). Statistical sig-
niﬁcance for differences was evaluated by one- or two-way ANOVA, as
appropriate, using Fisher least signiﬁcant differences test for post hoc
determination.
RESULTS
Impact of TNF-a treatment on human skeletal muscle
cells. Human myotubes were cultured for 24 h with 20 ng/mL
TNF-a. Cells treated with TNF-a showed decreased IRS-1
protein expression (Fig. 1A), and a diminution of both IRS-1
tyrosine (85% vs. untreated control, P , 0.01) and Akt
(Ser497) phosphorylation (54% vs. untreated control, P ,
0.01) after insulin stimulation (representative Western blot)
(Fig. 1B). This validates the experimental model, conﬁrming
that TNF-a induced insulin resistance as expected (17). The
impact of TNF-a on myotube death was also examined. At
a concentration of 20 ng/mL, TNF-a (as used in the current
study) had no impact on human skeletal muscle cell death
at any time up to 72 h (Fig. 1C). However, there was a
signiﬁcant decrease of cell death at 24 h using 10 ng/mL
TNF-a, but an increase at 40 ng/mL (Fig. 1D), albeit with ,2%
of the cells being TUNEL-positive even under these latter
conditions.
Myokine expression and secretion from human skeletal
muscle cells (myotubes) treated with or without TNF-a.
Human myotubes were cultured for up to 24 h with (TNF-a–
treated insulin-resistant myotubes [TMs]) or without (control
myotubes [CMs]) 20 ng/mL TNF-a. After 8 h, mRNA ex-
pression of 128 candidate genes for inﬂammatory cytokines
and their receptors were analyzed using Oligo nucleotide
array membranes. Insulin-resistant myotubes (+ TNF-a)
showed increased expression of 19 cytokine genes (Fig. 2A).
This was conﬁrmed and further quantiﬁed by quantitative RT-
PCR (Fig. 2B). To determine whether such cytokines were
released to the medium, conditioned media were collected
after 24 h, and candidate cytokines were measured. Using an
antibody array allowing for detection of 79 proteins in this
l a r g ef a m i l y ,w ew e r ea b l et oc o n ﬁrm that CCL5, CXCL10,
CXCL2, IL-6, IL-8, CCL2, CCL7, CXCL6, CXCL3, and CXCL1
were detectable and increased in the medium from TNF-a–
treated human myotubes when compared with untreated
myotubes (Fig. 3A and B), with increases ranging from
2.7-fold (osteoprotegrin) to 87-fold (Gro-a). Absolute
concentrations of IL-8, IL-6, and TNF-a in TMs were
measured independently (n = 2): IL-8, 3.50 ng/mL; IL-6,
2.5 ng/mL; TNF-a,1 8n g / m L .T N F - a was measured to
conﬁrm its stability in the conditioned medium (initial con-
centration 20 ng/mL).
Impact of conditioned medium from human myotubes
with different insulin sensitivity on primary sorted
b-cells. We had shown that TNF-a itself inhibits glucose-
stimulated insulin secretion (GSIS) but does not impact
growth or survival of b-cells (11). We now wished to de-
termine the effect on these b-cell parameters of condi-
tioned medium from TMs or CMs. To this end, b-cells were
treated for 48 h with either CMs or TMs, with BrdU added
during the last 24 h. Only rat b-cells were used to measure
proliferation, because adult human b-cells fail to prolifer-
ate to any meaningful extent in vitro (21). Because we
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above), an additional control condition involved CMs
“spiked” with 20 ng/mL TNF-a immediately before adding
it to the b-cells (CM + TNF-a). There was a dramatic
decrease in rat primary b-cell proliferation treated with
TMs when compared with CMs or CM + TNF-a (Fig. 4A).
This is the ﬁrst direct demonstration that products se-
creted from insulin-resistant (but not control) skeletal
muscle can impact negatively on b-cells. Interestingly,
CMs induced a signiﬁcant increase in b-cell proliferation
when compared with the control condition without CMs,
suggesting a beneﬁcial, mitogenic effect of products re-
leased by untreated (normally insulin-sensitive) myotubes
(Fig. 4A).
Both rat and human primary (sorted) b-cells were used
to evaluate the impact of TMs (24 h) on cell death and
insulin secretion. Neither CMs nor the addition of TNF-a to
such medium (CM + TNF-a) had any effect on b-cell ap-
optosis. However, TMs induced a sixfold increase in pri-
mary b-cell death (Fig. 4B and C). GSIS was signiﬁcantly
decreased in both rat and human primary b-cells treated
with either TMs or CM + TNF-a with no change in basal
insulin secretion (Fig. 4D and E, respectively). Using both
rat and human primary sorted b-cells, CMs alone (but not
CM + TNF-a)i n d u c e das i g n i ﬁcant increase in GSIS (Fig. 4D
and E), conﬁrming the beneﬁcial effects of CMs from
myotubes that were seen for proliferation of rat b-cells.
Taken together, these results document the existence of
products secreted from myotubes that impact either pos-
itively or negatively on pancreatic b-cell function, pro-
liferation, and survival.
Dual effects of conditioned medium from skeletal
muscle on Akt and extracellular signal–related kinase
phosphorylation in b-cells. We and others have dem-
onstrated that activation of the insulin signaling pathway
(via IRS-2) is necessary for b-cell survival, proliferation,
and GSIS (22–25). In order to explore the possible impact
of conditioned medium from skeletal muscle on this
pathway, rat primary b-cells were cultured in the presence
of CMs or TMs for 24 h. After this, cells were handled
exactly as for the measurement of GSIS. Phosphorylation
of both Akt and extracellular signal–related kinase (ERK)
FIG. 1. Effect of TNF-a on insulin sensitivity and apoptosis in human skeletal muscle cells. A: Human myotubes were cultured 24 h 6 20 ng/mL
TNF-a, and IRS-1 protein expression was measured by Western blot (normalized to actin). Mean 6 SE, 5 independent experiments. B: 24 h after
incubation with TNF-a, human skeletal muscle cells were treated with 100 nmol/L insulin either for 5 min to induce IRS-1 tyrosine phosphorylation
or 10 min to measure Akt phosphorylation. Representative immunoblots are shown for IRS-1 tyrosine (Tyr) phosphorylation (upper panel) and
Akt Ser479 phosphorylation (lower panel). C: Effect of different times of TNF-a treatment (20 ng/mL) on human skeletal muscle cell death
measured by TUNEL assay. n = 5 independent experiments. D: Effect of different TNF-a concentrations (24 h) on human primary skeletal muscle
cell death measured by TUNEL assay. n = 5 independent experiments; *P < 0.05 vs. control. IP, immunoprecipitation; IB, immunoblotting.
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ished this to the same extent as TNF-a on the background
of CM (Fig. 5A and B) suggesting this to be TNF-a–
dependent. Conversely, Akt (but not ERK) phosphoryla-
tion was increased in CM-treated b-cells under basal (but
not glucose-stimulated) conditions (Fig. 5A), which could
explain in part increased proliferation of b-cells cultured
with such conditioned medium (Fig. 4A)( 2 6 ) .
Dual effects of conditioned medium from skeletal
muscle on phosphorylation of substrates of Akt in
b-cells. We have demonstrated that AS160 is phosphory-
lated in response to glucose in b-cells and is involved in
GSIS as well as b-cell survival (22). As observed for Akt,
TM and TNF-a treatment prevented AS160 phosphoryla-
tion in response to glucose (Fig. 5C). Because AS160 is just
one of the multiple substrates that can be phosphorylated
by Akt, we explored the total pattern of such substrates
after glucose stimulation. As shown in Fig. 5D, glucose
induced the phosphorylation of several Akt substrate pro-
teins, while TM treatment prevented it for nearly all these
proteins (Fig. 5D, black crosses). Given the similar pattern
obtained using TM versus CM + TNF-a, this effect was again
presumed to be driven by the TNF-a that was still present
in TM. In the basal condition, phosphorylation of AS160
(Fig. 5C) and other yet-to-be-identiﬁed Akt substrate pro-
teins (Fig. 5D, white crosses) were increased when primary
rat b-cells were treated 24 h with CMs. Here again, these
results can explain the positive impact of CM on survival
and GSIS when primary rat b-cells were treated with CMs.
Dual effects of conditioned medium from myotubes
on IRS-1 and -2 mRNA and protein expression in
b-cells. IRS-1 and -2 have been shown to be central in both
insulin production and secretion (27,28). Therefore, we
explored the impact of conditioned media on IRS-1 and -2
expression. CM treatment induced an increase of protein
and mRNA expression for IRS-1 and -2 (Figs. 5E and F and
FIG. 2. Effect of TNF-a on expression of cytokine genes in human skeletal muscle cells. A: Human myotubes were cultured 8 h 6 20 ng/mL TNF-a,
and cytokine mRNA levels were monitored by hybridization to Oligo nucleotide array membranes. White circles show modiﬁed mRNA levels be-
tween the two conditions on representative membranes out of four different experiments. B: Cytokine mRNA levels were measured by quantitative
RT-PCR (qRT-PCR). The data are the mean value of four independent experiments, and mRNA expression levels were normalized to cyclophilin A.
HM + TNF, human skeletal muscle cells after 8-h culture with TNF-a; HM, human skeletal muscle cells after 8-h culture without TNF-a.
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CMs. Surprisingly, TM treatment increased IRS-1 protein
expression despite the presence of TNF-a in this medium
(Fig. 5E). There was, however, no such change in IRS-1
mRNA levels (Fig. 6A). By contrast, TM treatment de-
creased both IRS-2 protein and mRNA expression when
compared with CMs, whereas TNF-a had only an impact
on IRS-2 protein expression (Figs. 5F and 6B).
MAP4K4 mediates the effect of TMs on proliferation,
apoptosis, and GSIS in rat primary b-cells. MAP4K4
has been shown to mediate TNF-a action in adipose tissue,
skeletal muscle, and b-cells (11,17,29). In rat primary
b-cells, the amount of MAP4K4 mRNA was increased by
60 and 40% after either TNF-a or TM treatment for 24 h
(Fig. 6C). Unfortunately, there is no available antibody in
rats to monitor MAP4K4 protein levels by Western blot,
and it also is not possible to measure its activity. We
therefore adopted an indirect method to evaluate the im-
portance of MAP4K4 modulation by TMs. Transfection of
primary rat b-cells with small interfering RNA decreased
MAP4K4 mRNA expression by 60% in primary b-cells
treated with TMs (11). Rat primary b-cells lacking MAP4K4
were partially resistant to TM action on proliferation (Fig. 6D)
and totally protect against TM-induced apoptosis and its
impact on GSIS (Fig. 6E and F). These data suggest that
MAP4K4 is an important mediator of TM action on pan-
creatic b-cells and that TM can impact on MAP4K4 activity
independently of TNF-a.
Impact of IL-1RA, IL-6 receptor blockade, and GLP-1
on effects of TMs on primary rat b-cells. We show
above that TMs decrease b-cell proliferation, survival, and
GSIS (Fig. 4). We also show that human myotubes treated
with TNF-a for 24 h show an increase of several cytokines
including IL-1b (Figs. 2 and 3), which has been shown to
be involved in type 2 diabetes (30,31). Therefore, we de-
cided to explore whether pretreatment of b-cells with IL-
1RA, the natural soluble IL-1 receptor antagonist, could
prevent TM effects on b-cells. IL-1RA treatment failed to
prevent TM action on either GSIS (data not shown) or
proliferation (Fig. 7A), whereas TM action on cell death
was prevented (Fig. 7B). IL-1RA treatment did also induce
a decrease of proliferation in the control condition and
CM-treated b-cells. This seemingly paradoxical observa-
tion can be explained by the fact that b-cells plated as here
on extracellular matrix secrete low levels of IL-1b that
impact positively on b-cell survival (32), which is in keeping
with the established bimodal effects of this cytokine on
b-cells (33).
FIG. 3. Effect of TNF-a on human skeletal muscle cell cytokine secretion. A: Human myotubes were cultured 24 h 6 20 ng/mL TNF-a, and cytokine
levels in the conditioned media were monitored by hybridization to human chemokine + cytokine array membranes. White circles show modiﬁed
protein levels between the two conditions on representative membranes from three different experiments. B: Each membrane was quantiﬁed using
Multi Gauge software, and the intensity was normalized to internal positive controls for comparison. n = 3 independent experiments. TM, medium
from human skeletal muscle cells cultured 24 h with TNF-a; CM, medium from human skeletal muscle cells cultured 24 h without TNF-a.
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skeletal muscle and pancreas could be mediated by IL-6
(10). To evaluate this possibility, rat primary b-cells were
treated with IL-6 receptor antagonist (Sant-7) or a human
anti–IL-6 receptor antibody (AF-227-NA) to block IL-6 ac-
tion on b-cells. Under the present experimental conditions,
neither means of IL-6 receptor blockade was able to block
TM effects on rat primary b-cell proliferation, apoptosis, or
GSIS (data not shown). Nevertheless, blocking the IL-6
receptor did completely inhibit the increase of b-cell pro-
liferation evoked by CMs (data not shown).
Studies have shown that GLP-1 treatment can protect
b-cells from the negative actions of cytokines (34,35) and
also enhances primary rat b-cell proliferation (21). There-
fore we have explored if GLP-1 treatment could protect
b-cells against the detrimental effects evoked by TMs. As
expected, primary rat b-cells pretreated with GLP-1
showed an increase in proliferation under basal conditions
and also after CM treatment (Fig. 7C). However, pretreat-
ment with GLP-1 induced only a very small—albeit
signiﬁcant—increase in proliferation of cells treated with
TMs (Fig. 7C), whereas such treatment protected totally
the b-cells from TM action on apoptosis (Fig. 7D). GLP-1
treatment failed to protect against the decrease in GSIS
following 24-h culture with TMs (data not shown).
TNF-a antibody blocks TM action only on GSIS. We
have published that treatment with TNF-a alone can im-
pair GSIS in primary rat and human b-cells (11) without
affecting proliferation of apoptosis. Therefore, we ex-
plored directly which actions of TMs on primary rat b-cells
were because of the presence of TNF-a in this conditioned
medium using an antibody toward TNF-a (Ethanercept).
FIG. 4. Effect of conditioned medium on primary b-cell proliferation, survival, and GSIS. Conditioned medium was obtained by culturing human
myotubes for 24 h with (TM) or without (CM) 20 ng/mL TNF-a. Additional control conditions were as follows: CTRL, culture medium not pre-
viously exposed to skeletal muscle cells; CM + TNF, 20 ng/mL TNF-a added to CM immediately before exposure to b-cells. A: Proliferation of rat
primary b-cells measured by BrdU incorporation. Cells were grown under standard culture conditions (20% FCS, 11.2 mmol/L glucose) and treated
for 48 h with the different conditioned media; BrdU was added for the last 24 h. b-Cells were identiﬁed by insulin immunoﬂuorescence. n =7
independent experiments. B and C: Rat and human primary b-cell apoptosis. Cell death was measured by TUNEL. n = 7 (rats) and n = 5 (human)
independent experiments. *P < 0.05. D and E: Glucose-stimulated insulin secretion from rat and human primary b-cells measured during 60 min at
2.8 mmol/L glucose (white bars = basal secretion) following by 60 min at 16.7 mmol/L glucose (dark bars = stimulated secretion). Secretion is
expressed as a percentage total insulin content. n = 7 (rats) and n = 5 (human) independent experiments. *P < 0.05.
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TM action on GSIS. This was accompanied by an increase
in basal secretion (Fig. 7E). However, trapping of TNF-a
remained without effect on TM action on proliferation and
apoptosis (Fig. 7F and G), conﬁrming that these effects are
because of the impact of factors secreted from TNF-a–
treated myotubes and not because of TNF-a present in this
conditioned medium. Interestingly, Ethanercept treatment
increased apoptosis and decreased proliferation in rat
b-cells cultured for 48 h with CMs (Fig. 7F and G). These
results lead us to hypothesize that TNF-a at low levels in
CMs could act positively by itself or in combination with
other myokines on b-cell survival and proliferation. Our
combined data with Ethanercept and MAP4K4 silencing
reinforce the conclusion that TM action on proliferation
and survival is TNF-a–independent and mediated by
MAP4K4 activation by factors secreted by insulin-resistant
myotubes.
DISCUSSION
To understand the mechanism involved in type 2 diabetes
development, peripheral insulin resistance and b-cell func-
tion have to be studied in parallel (36,37). Low-grade sys-
temic inﬂammation is also a feature of obesity and diabetes
(38), raising the hypothesis that elevated cytokine levels
may contribute to insulin resistance and decreased b-cell
functional mass (39). Nonmuscle-derived TNF-a contrib-
utes to insulin resistance in human skeletal muscle (16,17)
and can also inhibit insulin secretion (11). Nowadays,
skeletal muscle is accepted as an endocrine organ (40). This
study reports that human myotubes produce and release
FIG. 5. Action of conditioned medium on Akt, ERK, AS160, and Akt substrates phosphorylation after glucose stimulation, or IRS-1 and -2 protein
expression in rat primary b-cells. Conditioned media and abbreviations as described in the legend to Fig. 3. After 24-h culture in conditioned
medium, b-cells were incubated 1 h at 2.8 mmol/L or 16.7 mmol/L glucose (Glc). Open bars = 2.8 mmol/L glucose; closed bars = 16.7 mmol/L glucose.
Western blots were scanned and data normalized to total protein or actin as indicated. N = 3 independent experiments. A: Akt Ser 473
phosphorylation. *P < 0.05; **P < 0.01. B: ERK1/2 phosphorylation. **P < 0.01. C: AS160 phosphorylation. *P < 0.05; **P < 0.01. D: Ser/Thr
phosphorylation of Akt substrates (white crosses = CM effect; black crosses = TM effect). E and F: IRS-1 (E) and IRS-2 (F) protein expression.
*P < 0.05. CTRL, control.
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sensitivity, adding to the list of previously known myo-
kines (41,42). This was achieved using a candidate ap-
proach, and an unbiased screening would likely reveal yet
more.
We have also focused on the possible endocrine impact
of these myokines on sorted primary human and rat
b-cells. There was bimodal action with conditioned medium
from human CMs that are fully sensitive to insulin-exerted
beneﬁcial effects on b-cells with increased proliferation
and GSIS, whereas that from insulin-resistant myotubes
(TMs) exerted detrimental effects with increased apopto-
sis, and decreased proliferation and GSIS. Myokines like
IL-1b, IL-6, TNF-a, CCL5, MCP-1, IL-8, and CXCL10 are
good candidates for these latter, detrimental actions as
they have been shown to impact negatively on b-cell
function and survival (5,9–13). However, IL-RA, TNF-a
trapping, and IL-6 receptor blockade failed to completely
rescue b-cells from TM action, exemplifying the complex
nature of the cocktail of cytokines in this conditioned
medium. Meanwhile, GLP-1 treatment was able to rescue
primary b-cells from TM-mediated apoptosis, conﬁrming
its antiapoptotic properties (34). The data further indicate
that lower concentrations of cytokines secreted by insulin-
sensitive myotubes, as previously observed for IL-1b (33)
and conﬁrmed here for this cytokine as well as TNF-a
and IL-6, could have a positive action on b-cells in keeping
with bimodal action depending on concentration and the
biological context (33). Nevertheless, other myokines, al-
ready identiﬁed or not, could be involved in both the posi-
tive and negative effects of CMs or TMs.
In order to gain a more detailed understanding of the
underlying molecular pathways, we explored the signaling
pathways impacted in b-cells by the various conditioned
media and possible means to protect them from such ac-
tion. In b-cells, activation of the insulin-signaling pathway
is necessary to mediate glucose action (23) with IRS-2/Akt/
AS160 involved in GSIS (22). Moreover, IRS-2 is known to
be indispensable for b-cell function (43) while ERK acti-
vation has been shown to be involved in GSIS (44). TM
-
FIG. 6. Action of conditioned medium on IRS-1, IRS-2, and MAP4K4 mRNA expression and effect of MAP4K4 knockdown. Conditioned media and
abbreviations as described in the legend to Fig. 3. Rat primary b-cells were used for n = 5 independent experiments. A–C: IRS-1, IRS-2, and MAP4K4
mRNA expression were measured by quantitative real-time RT-PCR in b-cells. *P < 0.05. D–F: Proliferation (BrdU incorporation) (D) and apo-
ptosis (TUNEL) (E) were measured in b-cells transfected with scrambled (Scr) (open bars = Scr) or with MAP4K4 small interfering RNA (siRNA)
Si MAP4K4 (closed bars = Si MAP4K4). F: Insulin secretion was measured using b-cells transfected with scrambled (Scr) or with Si MAP4K4 and
incubated for 60 min at 2.8 mmol/L glucose (open bars) followed by 60 min at 16.7 mmol/L glucose (closed bars). *P < 0.05. CTRL, control.
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and its substrates including AS160. We also demonstrated
that glucose-stimulated phosphorylation of a number of
Akt substrates in rat primary b-cells was prevented by
TMs. Only a few of these Akt substrates have been iden-
tiﬁed in muscle and adipose tissue while nothing is known
in pancreatic b-cells aside from our previous work on
AS160 showing that this Akt substrate was indispensable
for GSIS (22). Conversely, CM treatment of primary sorted
b-cells increased phosphorylation of Akt and several Akt
substrates under basal conditions. This could partly explain
the positive impact of CMs on primary b-cells.
Protein and mRNA levels of IRS-2 were decreased by
TMs with a compensatory effect seeming to occur between
IRS-1 and -2 as both TMs and CMs induced an increase
of IRS-1 expression, while only CMs induced an increase
of IRS-2. This supports ﬁndings in other tissues that IRS-1
and -2 have separate and nonredundant function (45).
It has been shown that insulin resistance can be rescued
after MAP4K4 silencing in skeletal muscle and adipose
tissue (17,46) while another study reported that silencing
of MAP4K4 in macrophages can suppress systemic inﬂam-
mation and therefore prevent diabetes (29). In b-cells,
MAP4K4 silencing protects against TNF-a inhibition of GSIS
(11). Here we show that TM treatment increased signiﬁ-
cantly MAP4K4 gene expression in rat primary b-cells. Its
silencing prevented TM action on GSIS, which seems to be
TNF-a–dependent, and on b-cell proliferation and apopto-
sis, which is TNF-a–independent.
Inﬂammatory mechanisms have been suggested to con-
tribute as causative factors in the development of type 2
diabetes. It has been further postulated that the diabeto-
genic environment, including insulin resistance and low-
grade systemic and localized islet inﬂammation, contribute
toward b-cell “stunning” (47). Our results lead us to pro-
pose a new component of this complex paradigm. We thus
-
FIG. 7. Effect of IL-1RA, GLP-1, or anti–TNF-a on rat primary b-cells exposed to conditioned medium. Conditioned media and abbreviations as
described in the legend to Fig. 3. Rat primary b-cells were treated 48 h with IL-1RA (1 mg/mL) and conditioned medium. A: BrdU was added during
the last 24 h to measure proliferation. B: Conditioned medium added for the last 24 h and cell death was measured by TUNEL. C: Rat primary
b-cells were treated 48 h with conditioned medium, with or without GLP-1 (100 nmol/L), and BrdU was added the last 24 h to measure proliferation.
D: Rat primary b-cells were treated 48 h with or without GLP-1, and conditioned medium was added for the last 24 h. Cell death was measured as
described. n = 3 independent experiments. *P < 0.05; **P < 0.01. E: Insulin secretion was measured using rat primary b-cells treated for 24 h with
the different conditioned media with or without TNF-a blockade (2 ng/mL Ethanercept) and then incubated for 60 min at 2.8 mmol/L glucose (open
bars) followed by 60 min at 16.7 mmol/L glucose (closed bars); *P < 0.05. F and G: Rat primary b-cells treated with the different conditioned media
with or without Ethanercept and were used to assess cell death using TUNEL assay (F) and cell proliferation (G) as described. n = 4 independent
experiments; *P < 0.05 for TNF-a blockade. CTRL, control.
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muscle by TNF-a leads to secretion of myokines that im-
pact negatively on b-cell proliferation and survival. Of
course, this is just one in vitro model of human skeletal
muscle insulin resistance, and the panel of myokines se-
creted by myotubes rendered insulin resistant by other
means or taken directly from insulin-resistant patients may
be different from that induced by TNF-a: this is worthy
of further study. At present, there is little evidence for
elevated TNF-a in the skeletal muscle of individuals with
type 2 diabetes, whereas its contribution toward skeletal
muscle insulin resistance is well established (18). Never-
theless, assuming that it will prove possible to extrapolate
from the present artiﬁcial situation with myokine con-
centrations in the conditioned media that are arbitrary and
dependent on the in vitro conditions, to the clinical set-
ting, the identiﬁcation of these myokines and of this new
pathway for interorgan communication between skeletal
muscle and b-cells offers new insight into the pathological
process linking insulin resistance to b-cell failure and
opens the possibility for new therapeutic strategies for
preservation of functional b-cell mass in type 2 diabetes.
Collectively, our results regarding TM action on primary
b-cells combined with earlier data in these and other cell
types (11,17,29,46) place MAP4K4 as a novel target in the
effort to treat or prevent diabetes by addressing both pe-
ripheral insulin resistance and the loss of b-cell mass. Our
results also indicate a novel mechanism allowing for pro-
tection of b-cells by GLP-1. Finally, the beneﬁcial effects
of conditioned medium from insulin-sensitive myotubes
(CMs) raises the interesting prospect of identifying novel
molecules able to improve b-cell function, survival, and
proliferation while suggesting that communication from
skeletal muscle may contribute toward normal b-cell func-
tion and mass in healthy individuals.
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